CERS

Cerus is a genuine improving story, not a broken one. Its INTERCEPT Blood System has driven revenue from $160M (FY2021) to $234M (FY2025), a +16.1% latest-year gain, while the net loss has narrowed every single year — from -$54.4M to -$42.8M to -$37.5M to -$20.9M to -$15.6M. Operating loss is now just -$8.68M and the company generated positive operating cash flow of $4.84M in FY2025. That is a business converging toward breakeven, and at a P/S of 2.6 the market is not paying a rich multiple for the momentum. If the trajectory holds, the equity can re-rate toward profitability.

But this is not yet an investable buy. The loss is still structurally driven below the operating line: interest expense on the Term Loan ran $8.3M in FY2025 — larger than the entire operating loss — and SG&A of $80.9M rose 7% on 'increased workforce costs.' The balance sheet is stretched: liabilities are 2.44x equity, cash is only $20.0M (down 1.5%), and although total liquidity is $83.5M including $62.9M of short-term investments, operating cash flow fell 57% year-over-year and current liabilities jumped 58.5%. The accumulated deficit is -$1.08B, and the 10-K's forward-looking language explicitly flags 'our ability to continue as a going concern and our need for additional funding' — with shares already up 3.4%/yr, further dilution is a live risk.